Denosumab in Breast Cancer
Author:
- 5 November 2010
- journal article
- review article
- Published by Springer Nature in Current Oncology Reports
- Vol. 13 (1) , 1-4
Abstract
Bone destruction is mediated by osteoclasts, whose formation, function, and survival requires the receptor activator of NF-kB ligand (RANKL). Denosumab is a fully human monoclonal antibody to RANKL, thereby inhibiting osteoclast-mediated bone destruction, and blocks the vicious cycle of cancer-mediated bone disease. In breast cancer patients with bone metastases, denosumab was superior to zoledronic acid in delaying time to first on-study skeletal-related event (SRE; HR = 0.82; P = 0.01 superiority) and time to first and subsequent on-study SREs (HR = 0.77; P = 0.001). Overall survival, disease progression, and serious adverse events were similar between groups.Keywords
This publication has 24 references indexed in Scilit:
- Randomized Phase II Trial of Denosumab in Patients With Bone Metastases From Prostate Cancer, Breast Cancer, or Other Neoplasms After Intravenous BisphosphonatesJournal of Clinical Oncology, 2009
- Randomized Trial of Denosumab in Patients Receiving Adjuvant Aromatase Inhibitors for Nonmetastatic Breast CancerJournal of Clinical Oncology, 2008
- Effect of Anastrozole on Bone Mineral Density: 5-Year Results From the Anastrozole, Tamoxifen, Alone or in Combination Trial 18233230Journal of Clinical Oncology, 2008
- Basic Mechanisms Responsible for Osteolytic and Osteoblastic Bone MetastasesClinical Cancer Research, 2006
- Risk of Cancer Treatment—Associated Bone Loss and Fractures Among Women with Breast Cancer Receiving Aromatase InhibitorsClinical Breast Cancer, 2006
- Mechanisms of Disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasisNature Clinical Practice Oncology, 2006
- Mechanisms of Bone MetastasisNew England Journal of Medicine, 2004
- A novel molecular mechanism modulating osteoclast differentiation and functionBone, 1999
- Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and ActivationCell, 1998
- Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone DensityCell, 1997